|
|
Blood, 15 April 2006, Vol. 107, No. 8, pp. 3313-3320.
Prepublished online as a Blood First Edition Paper on December 20, 2005; DOI 10.1182/blood-2005-07-2823.
Previous Article | Next Article 
Submitted July 15, 2005
Accepted December 4, 2005
Cross-talk among Notch3, pre-TCR and Tal-1 in T-cell development and leukemogenesis
Claudio Talora, Samantha Cialfi, Christian Oliviero, Rocco Palermo, Monica Pascucci, Luigi Frati, Alessandra Vacca, Alberto Gulino, and Isabella Screpanti*
Department of Experimental Medicine and Pathology, University "La Sapienza", Roma, Italy
Department of Experimental Medicine, University of L'Aquila, L'Aquila, Italy
Department of Experimental Medicine and Pathology, University "La Sapienza", Roma, Italy; Neuromed Institute, Pozzilli, Italy
Department of Experimental Medicine and Pathology, University "La Sapienza", Roma, Italy; Istituto Pasteur-Fondazione Cenci Bolognetti, University 'La Sapienza', Roma, Italy
* Corresponding author; email: isabella.screpanti{at}uniroma1.it.
Integrated pathways are believed to determine hematopoietic cell fate and/or neoplastic transformation. Notch signaling has been shown to regulate T cell differentiation and leukemogenesis. However, specific target genes and molecular partners are not fully elucidated. We show that Notch3 activation sustains aberrant SCL/Tal1 overexpression and phosphorylation in mature thymocytes. Furthermore, we define the role of SCL/Tal1 as a component of an activator complex, including phosphorylated Tal1 and Sp1, that specifically enhances cyclin D1 expression and demonstrate that Tal1/Sp1 specifically co-occupy the D1 promoter in vivo, only in the presence of pre-TCR. We therefore conclude not only that cyclin D1 is a target of the Tal1/Sp1 complex, but also that Notch3 dependent activation of pre-TCR/ERK signaling regulates SCL/Tal1 function.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
J. T. Park, I.-M. Shih, and T.-L. Wang
Identification of Pbx1, a Potential Oncogene, as a Notch3 Target Gene in Ovarian Cancer
Cancer Res.,
November 1, 2008;
68(21):
8852 - 8860.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Xu, Q. Yu, R. Subrahmanyam, M. J. Difilippantonio, T. Ried, and J. M. Sen
{beta}-Catenin Expression Results in p53-Independent DNA Damage and Oncogene-Induced Senescence in Prelymphomagenic Thymocytes In Vivo
Mol. Cell. Biol.,
March 1, 2008;
28(5):
1713 - 1723.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. R. Gothert, R. L. Brake, M. Smeets, U. Duhrsen, C. G. Begley, and D. J. Izon
NOTCH1 pathway activation is an early hallmark of SCL T leukemogenesis
Blood,
November 15, 2007;
110(10):
3753 - 3762.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K.-A. Kim, J.-H. Kim, Y. Wang, and H. S. Sul
Pref-1 (Preadipocyte Factor 1) Activates the MEK/Extracellular Signal-Regulated Kinase Pathway To Inhibit Adipocyte Differentiation
Mol. Cell. Biol.,
March 15, 2007;
27(6):
2294 - 2308.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P.-Y. Chang, K. Draheim, M. A. Kelliher, and S. Miyamoto
NFKB1 Is a Direct Target of the TAL1 Oncoprotein in Human T Leukemia Cells.
Cancer Res.,
June 15, 2006;
66(12):
6008 - 6013.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|